Karim Iskander
Impact in
- Hematology top 5%
- Multiple Myeloma Research and Treatments
- Toxicology top 2%
- Bioactive Compounds and Antitumor Agents
Papers in
-
- Protein Degradation and Inhibitors 13
- Genomics, phytochemicals, and oxidative stress 5
- Ubiquitin and proteasome pathways 2
- Hematology 23
- Multiple Myeloma Research and Treatments 22
- Co-authors
- Ola Landgren (5 shared papers)Anil K. Jaiswal (5 shared papers)Roberto Barrios (3 shared papers)Hermann Einsele (2 shared papers)Amos Gaikwad (2 shared papers)Delwin J. Long (2 shared papers)Cory Brayton (2 shared papers)Marilène Paquet (2 shared papers)
- Journals
- Blood (8 papers)Cancer Research (3 papers)Leukemia (2 papers)Journal of Clinical Oncology (2 papers)Journal of Biological Chemistry (2 papers)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Karim Iskander
29 papers receiving 815 citations
Peers
Comparison fields: 5 of 88
- Hematology 296
- Toxicology 89
- Oncology 273
- Geriatrics and Gerontology 23
- Molecular Biology 462
Countries citing papers authored by Karim Iskander
This map shows the geographic impact of Karim Iskander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karim Iskander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karim Iskander more than expected).
Fields of papers citing papers by Karim Iskander
This network shows the impact of papers produced by Karim Iskander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karim Iskander. The network helps show where Karim Iskander may publish in the future.
Co-authors
The 25 scholars most cited alongside Karim Iskander, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 172 | |
| 2 | 2017 | 114 | |
| 3 | 2002 | 97 | |
| 4 | 2005 | 68 | |
| 5 | 2006 | 62 | |
| 6 | 2018 | 52 | |
| 7 | 2004 | 47 | |
| 8 | 2019 | 45 | |
| 9 | 2018 | 29 | |
| 10 | 2008 | 24 | |
| 11 | 2018 | 23 | |
| 12 | 2018 | 17 | |
| 13 | 2017 | 17 | |
| 14 | 2020 | 13 | |
| 15 | Obesity-related complications: few biochemical phenomena with reference to tumorigenesis. | 2013 | 9 |
| 16 | 2018 | 6 | |
| 17 | 2017 | 6 | |
| 18 | 2021 | 4 | |
| 19 | 2017 | 4 | |
| 20 | 2017 | 3 |
About Karim Iskander
Karim Iskander is a scholar working on Molecular Biology, Hematology, Oncology, Toxicology and Genetics, having authored 30 papers that have together received 826 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (22 papers), Protein Degradation and Inhibitors (13 papers), Cancer Treatment and Pharmacology (5 papers), Genomics, phytochemicals, and oxidative stress (5 papers), Bioactive Compounds and Antitumor Agents (5 papers), Peptidase Inhibition and Analysis (5 papers), Ubiquitin and proteasome pathways (2 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers). The work is most often cited by research in Hematology (296 citations), Toxicology (89 citations), Oncology (273 citations), Geriatrics and Gerontology (23 citations) and Molecular Biology (462 citations). Karim Iskander has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Ola Landgren, Anil K. Jaiswal, Roberto Barrios, Hermann Einsele, Amos Gaikwad, Delwin J. Long, Cory Brayton, Marilène Paquet, Robert Z. Orlowski and Marion Subklewe. Their work appears in journals such as Blood, Cancer Research, Leukemia, Journal of Clinical Oncology and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.